Global Insomnia Treatment Market by Treatment Type, Distribution Channel and Geography - Forecast to 2023 - ResearchAndMarkets.com

September 27, 2018

DUBLIN--(BUSINESS WIRE)--Sep 27, 2018--The “Global Insomnia Treatment Market - Segmented by Treatment Type, Distribution Channel, and Geography - Growth, Trends, and Forecast (2018 - 2023)” report has been added to ResearchAndMarkets.com’s offering.

The Insomnia Treatment Market is expected to grow at a CAGR of approximately 5.5% during the forecast period.

The insomnia drugs comprise of a wide range of patented drugs as well as generics. The patented drugs hold the larger share of the revenue in developed regions due to better reimbursement policies. On the other hand, generics & branded generics accounted for the largest revenue in developing and underdeveloped regions.

Zolpidem is the highest selling insomnia treatment drug, owing to its effectiveness and easy availability. In terms of sales channel distribution, the prescription segment accounted for the largest share of over 80% of the total market revenue in 2017. This segment is expected to maintain its dominance throughout the forecast period owing to an increase in the use of prescription pharmaceuticals.

Key Highlights

Increasing Stress Due to the Highly Active Lifestyle of Individuals to Induce a Surge in the Market Patient Non-Adherence due to Characteristic Side Effects of Sleeping Pills to Impede the Growth of the Market North America to Maintain the Lead as the Largest Shareholder

Major Developments in the Market

Cerve Inc., a privately-held healthcare company is preparing to launch its FDA-cleared insomnia device. The company announced today the closing of a $38 million Series B round of financing led by KKR, a leading global investment firm. Also participating in the financing are existing shareholders Versant Ventures, Arboretum Ventures, and Partner Ventures.

Key Topics Covered

1. Introduction

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)

7. Market Segmentation

8. Competitive Landscape

9. Key Players in Insomnia Treatment

Ebb Therapeutics Merck & Co. Mylan N.V. Paratek Pharmaceuticals Inc. Pfizer Inc. Sanofi S.A. Sumitomo Dainippon Pharma Co. Ltd. Takeda Pharmaceutical Company Ltd. Teva Pharmaceutical Industries Ltd. Vanda Pharmaceuticals Inc.

For more information about this report visit https://www.researchandmarkets.com/research/xlfbbc/global_insomnia?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180927005648/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/27/2018 11:22 AM/DISC: 09/27/2018 11:22 AM


Update hourly